A new risk assessment score developed by researchers at Dana-Farber Cancer Institute, the Broad Institute of MIT and Harvard, and Massachusetts General Hospital reveals how multiple myeloma, a form of ...

Agency drug reviewers had questioned patient risk criteria and the efficacy endpoint used in a key trial supporting J&J's ...

A new risk assessment score developed by researchers at Dana-Farber Cancer Institute and the Broad Institute of MIT and Harvard reveals how multiple myeloma, a form of blood cancer, begins and ...

A new risk assessment score developed by researchers at Dana-Farber Cancer Institute and the Broad Institute of MIT and ...

In the evolving landscape of haematologic cancers, the concept of minimal residual disease, also known as measurable residual ...

Farber Cancer Institute and the Broad Institute of MIT and Harvard reveals how multiple myeloma, a form of blood cancer, begins and progresses from precancerous to malignant states by tracing DNA ...

A new risk assessment score developed by researchers at Dana-Farber Cancer Institute and the Broad Institute of MIT and ...

Markers of aggressive disease include elevated ... in the percentage of patients with high-risk newly diagnosed multiple myeloma to about 20%. ASCT remains a treatment standard in newly diagnosed ...

How cancer patients relying on daratumumab feel physically before starting the therapy can predict how long they will live and how well they will respond to the anti- multiple myeloma (MM) drug, ...

Patients with lower physical function before starting daratumumab therapy showed greater treatment benefit than those who ...

These drugs target some of the most pressing cancer types, including multiple myeloma, breast cancer, and bladder cancer ...